← Back to Search
Thymidylate Synthase And Excision Repair Cross-Complementing Group-1 As Predictors Of Responsiveness In Mesothelioma Patients Treated With Pemetrexed/Carboplatin
P. A. Zucali, E. Giovannetti, A. Destro, M. Mencoboni, G. L. Ceresoli, L. Gianoncelli, E. Lorenzi, F. De Vincenzo, M. Simonelli, M. Perrino, A. Bruzzone, E. Thunnissen, G. Tunesi, L. Giordano, M. Roncalli, G. Peters, A. Santoro
Published 2011 · Medicine
Download PDFAnalyze on Scholarcy
Purpose: The pemetrexed/platinum agent combination represents the standard of care in first-line treatment for malignant pleural mesothelioma (MPM). However, there are no established indicators of responsiveness that can be used to optimize the treatment. This retrospective study aimed to assess the role of excision repair cross-complementing group-1 (ERCC1) and thymidylate synthase (TS) in tumors, and correlate expression levels and polymorphisms of these key determinants of drug activity with the outcome of MPM patients treated with carboplatin/pemetrexed in first-line setting. Experimental design: Analysis of TS and ERCC1 polymorphisms, mRNA and protein expression was done by PCR and immunohistochemistry [with the H-score (histologic score)] in tumor specimens from 126 MPM patients, including 99 carboplatin-/pemetrexed-treated patients. Results: A significant correlation between low TS protein expression and disease control (DC) to carboplatin/pemetrexed therapy (P = 0.027), longer progression-free survival (PFS; P = 0.017), and longer overall survival (OS; P = 0.022) was found when patients were categorized according to median H-score. However, patients with the higher tertile of TS mRNA expression correlated with higher risk of developing progressive disease (P = 0.022), shorter PFS (P < 0.001), and shorter OS (P < 0.001). At multivariate analysis, the higher tertile of TS mRNA level and TS H-score confirmed their independent prognostic role for DC, PFS, and OS. No significant associations were found among ERCC1 protein expression, TS and ERCC1 polymorphisms, and clinical outcome. Conclusions: In our series of carboplatin-/pemetrexed-treated MPM patients, low TS protein and mRNA levels were significantly associated to DC, improved PFS, and OS. Prospective trials for the validation of the prognostic/predictive role of TS in MPM patients treated with pemetrexed-based regimens are warranted. Clin Cancer Res; 17(8); 2581–90. ©2011 AACR.
This paper references
Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells
E. Giovannetti (2008)
Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of colorectal cancer patients
R Mauritz (2009)
DolanME.Molecularmechanisms of resistance and toxicity associated with platinating agents
CA Rabik (2007)
The European mesothelioma epidemic
J. Peto (1999)
Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer.
E. Villafranca (2001)
Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
J. S. Ryu (2004)
Personalized Medicine: Elusive Dream or Imminent Reality?
L. Lesko (2007)
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
P. Zucali (2008)
New prognostic indicator for non‐small‐cell lung cancer, quantitation of thymidylate synthase by real‐time reverse transcription polymerase chain reaction
Y. Shintani (2003)
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
K. Olaussen (2006)
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer
D. Park (2002)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
A. Ruzzo (2007)
In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression
Axel-Rainer Hanauske (2007)
ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
S. Smith (2007)
A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
K. Darcy (2007)
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
L. Righi (2010)
Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.
O. Røe (2010)
Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
E. Giovannetti (2007)
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
C. Shih (1997)
Pharmacogenetics goes genomic
D. Goldstein (2003)
Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis
S. Wei (2011)
Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung
H. Hashimoto (2006)
Thymidylate synthase in situ protein expression and survival in stage I nonsmall‐cell lung cancer
Zhong Zheng (2008)
[Malignant pleural mesothelioma].
Q. Kong (1983)
A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil
B. Iacopetta (2001)
Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase.
E. Chu (1991)
Association between polymorphisms of ERCC 1 and XPD and survival in non - small - cell
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Pharmacogenetics goes geno
LJ Lesko (2003)
Repair of U/G and U/A in DNA by UNG2-associated repair complexes takes place predominantly by short-patch repair both in proliferating and growth-arrested cells.
M. Akbari (2004)
Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer
G. Bepler (2008)
Pharmacogenomics in non-small-cell lung cancer chemotherapy.
R. Danesi (2009)
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications
S. Chattopadhyay (2007)
ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
H. Jun (2008)
Genomic events associated with progression of pleural malignant mesothelioma
S. V. Ivanov (2009)
Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal can
DJ Park (2001)
Polymorphisms in ERCC1 and ERCC2/XPD and Survival in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin Based Chemotherapy.
Jeong-Seon Ryu (2003)
Clin Cancer Res Clinical Cancer Research
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
J. Sigmond (2003)
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
Pharmacogenetics of Colon Cancer and Potential Implications for 5- Fluorouracil-Based Chemotherapy
R. M. Peters (2006)
Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors
P. Ceppi (2008)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Molecular mechanisms of resistance and toxicity associated with platinating agents.
C. Rabik (2007)
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.
Zhong Zheng (2007)
Cytotoxic effects of pemetrexed in gastric cancer cells
J. Kim (2005)
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.
R. Mauritz (2009)
DNA repair in humans.
A. Sancar (1995)
Expression as Predictors of Outcome in MPM www
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
H. Kwon (2007)
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
This paper is referenced by
Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
S. H. Lee (2013)
The biomolecular era for thoracic surgeons: the example of the ESTS Biology Club.
I. Opitz (2014)
Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Lukas Frischknecht (2015)
Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma
D. S. Lustgarten (2013)
Recent Advances in Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma
C. Asteriou (2013)
ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
S. Dosso (2013)
Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed
E. Arévalo (2013)
Customizing chemotherapy in thoracic malignancies based on ERCC1 expression
Jens Benn Sørensen (2013)
The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma.
N. Erčulj (2012)
Malignant Pleural Mesothelioma: From the Bench to the Bedside
P. Astoul (2012)
Is DNA repair a potential target for effective therapies against malignant mesothelioma?
I. Fuso Nerini (2020)
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
Giovanna Li Petri (2020)
Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
K. Goričar (2014)
Biomarkers and prognostic factors for malignant pleural mesothelioma.
P. Vigneri (2015)
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
E. Giovannetti (2011)
Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesothelioma.
M. Disselhorst (2020)
Polymorphisms correlated with the clinical outcome of locally advanced or metastatic colorectal cancer patients treated with ALIRI vs. FOLFIRI
A. Barcelos (2013)
ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
Angelica SonzogniRoberto (2013)
Characterization of malignant pleural mesothelioma : possibilities for an individualized therapeutic arsenal
Adam Szulkin (2014)
Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.
Nitzan Gonen (2012)
What's new in mesothelioma.
V. Ascoli (2018)
Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma
K. Goričar (2017)
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
I. Cavallari (2019)
Inhibition of MDM 2 via Nutlin-3 A : A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM 2-Induced Inactivation of Wild-Type P 53
Robert F H Walter (2018)
Reduced Folate Carrier and Folylpolyglutamate Synthetase, but not Thymidylate Synthase Predict Survival in Pemetrexed-Treated Patients Suffering from Malignant Pleural Mesothelioma
F. Mairinger (2013)
PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA
FATTORI PROGNOSTICI (2012)
Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial
D. Fennell (2020)
The issue of studies evaluating biomarkers which predict outcome after pemetrexed-based chemotherapy in malignant pleural mesothelioma.
F. Mairinger (2013)
Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open.
E. Giovannetti (2016)
Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy
Sabrina Borchert (2019)
"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma.
E. Giovannetti (2013)
Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer
D. Del Bufalo (2014)See more